Drug Profile
Research programme: cyclo-oxygenase-2 selective inhibitors - Euclises Pharmaceuticals/Guangzhou Institutes of Biomedicine and Health
Alternative Names: Compound 1014; ECP 1014; GIBH-1014Latest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Guangzhou Institutes of Biomedicine and Health
- Developer Euclises Pharmaceuticals; Guangzhou Institutes of Biomedicine and Health
- Class Benzopyrans; Carboxylic acids; Small molecules
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Cancer; Inflammation; Pain
Most Recent Events
- 17 Feb 2023 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in China (PO)
- 18 Jun 2021 Euclises Pharmaceuticals plans a phase I trial for Solid tumours (Second-line therapy or greater) in China (PO, Capsule) (NCT04930354)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in China (PO, Tablet)